Stay updated on Biogen Press Releases

Sign up to get notified when there's something new on the Biogen Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Biogen Press Releases page

  1. Check
    2 days ago
    Change Detected
    Summary
    A new June 29, 2026 news item was added announcing Biogen's plan to highlight its Alzheimer’s portfolio at AAIC 2026, including Phase 2 CELIA data for Diranersen. The May 14, 2026 topline results entry for the CELIA study of Diranersen was removed.
    Difference
    4%
    Check dated 2026-07-03T21:52:28.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    Two new News items were added for June 17 (Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.) and June 16 (Biogen to Report Second Quarter 2026 Financial Results July 29, 2026). Two older May updates (FDA Priority Review of LEQEMBI subcutaneous dose and Bank of America conference participation) were removed.
    Difference
    4%
    Check dated 2026-06-19T17:52:51.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    New 2026 press releases were added (including FDA Breakthrough Designation for Salanersen, EULAR update on Dapirolizumab Pegol, and upcoming kidney presentations) and older 2026 items (first-quarter results, acquisition-related items, and related agreements) were removed from the list.
    Difference
    5%
    Check dated 2026-06-05T09:32:48.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    New May 28, 2026 Biogen Announces Webcast of Annual Meeting of Stockholders added to the News page. Removed March 30, 2026 FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy.
    Difference
    4%
    Check dated 2026-05-29T05:51:18.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    A new May 21, 2026 press release about Biogen and Denali Therapeutics' Phase 2b LUMA study in early-stage Parkinson’s disease was added. A March 28, 2026 Litifilimab trial entry in cutaneous lupus erythematosus was removed.
    Difference
    4%
    Check dated 2026-05-22T04:44:52.000Z thumbnail image
  8. Check
    52 days ago
    Change Detected
    Summary
    Three new news entries were added for May 14 and May 8, 2026, including Biogen's acquisition of Apellis Pharmaceuticals, topline results from the CELIA study, and an update on LEQEMBI dosing. Three older March 2026 items were removed from the listing.
    Difference
    4%
    Check dated 2026-05-14T22:30:28.000Z thumbnail image

Stay in the know with updates to Biogen Press Releases

Enter your email address, and we'll notify you when there's something new on the Biogen Press Releases page.